Form 4: United Therapeutics Chairperson & CEO Rothblatt Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4 Filing
Martine Rothblatt, Chairperson & CEO of United Therapeutics, executed a series of stock option exercises and sales on July 31, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, Chairperson & CEO of United Therapeutics, filed a Form 4 disclosing changes in beneficial ownership of the company's stock on August 2, 2024.
- On July 31, 2024, Rothblatt exercised 3,600 stock options at a price of $129.49 per share.
- Simultaneously, Rothblatt sold a total of 3,600 shares in multiple transactions at prices ranging from $312.525 to $323.915.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- The plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
- Following these transactions, Rothblatt directly owns 776 shares of common stock and indirectly owns shares through various trusts and spousal holdings.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an insider, with no inherent positive or negative sentiment.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Comparison to Industry Standards
- Executive compensation practices, including stock options, are common across the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
- The use of 10b5-1 trading plans is a standard method for insiders to sell shares while avoiding accusations of insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Original Expiration Date of Stock Options |
| 08/04/2023 | Date of establishment of the 10b5-1 trading plan |
| 07/31/2024 | Date of stock option exercise and sale transactions |
| 08/02/2024 | Date of Form 4 filing |
| 08/31/2024 | Potential end date of the 10b5-1 trading plan |
| 12/31/2024 | Expiration date of the tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.